SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:88935f5f-2d4d-4f16-bd62-42217f8dd08f"
 

Search: onr:"swepub:oai:lup.lub.lu.se:88935f5f-2d4d-4f16-bd62-42217f8dd08f" > Novel Selective Gal...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Bum-Erdene, KhuchtumurGriffith University (author)

Novel Selective Galectin-3 Antagonists Are Cytotoxic to Acute Lymphoblastic Leukemia

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2022-04-15
  • American Chemical Society (ACS),2022
  • 15 s.

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:88935f5f-2d4d-4f16-bd62-42217f8dd08f
  • https://lup.lub.lu.se/record/88935f5f-2d4d-4f16-bd62-42217f8dd08fURI
  • https://doi.org/10.1021/acs.jmedchem.1c01296DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Galectin-3 is a β-galactoside-specific, carbohydrate-recognizing protein (lectin) that is strongly implicated in cancer development, metastasis, and drug resistance. Galectin-3 promotes migration and ability to withstand drug treatment of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells. Due to high amino acid conservation among galectins and the shallow nature of their glycan-binding site, the design of selective potent antagonists targeting galectin-3 is challenging. Herein, we report the design and synthesis of novel taloside-based antagonists of galectin-3 with enhanced affinity and selectivity. The molecules were optimized by in silico docking, selectivity was established against four galectins, and the binding modes were confirmed by elucidation of X-ray crystal structures. Critically, the specific inhibition of galectin-3-induced BCP-ALL cell agglutination was demonstrated. The compounds decreased the viability of ALL cells even when grown in the presence of protective stromal cells. We conclude that these compounds are promising leads for therapeutics, targeting the tumor-supportive activities of galectin-3 in cancer.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Collins, Patrick M.Griffith University (author)
  • Hugo, Matthew W.Griffith University (author)
  • Tarighat, Somayeh S.Children's Hospital Los Angeles (author)
  • Fei, FeiChildren's Hospital Los Angeles (author)
  • Kishor, ChandanGriffith University (author)
  • Leffler, HakonLund University,Lunds universitet,Avdelningen för mikrobiologi, immunologi och glykobiologi - MIG,Institutionen för laboratoriemedicin,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Division of Microbiology, Immunology and Glycobiology - MIG,Department of Laboratory Medicine,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments(Swepub:lu)mmb-hle (author)
  • Nilsson, Ulf J.Lund University,Lunds universitet,Centrum för analys och syntes,Kemiska institutionen,Institutioner vid LTH,Lunds Tekniska Högskola,Centre for Analysis and Synthesis,Department of Chemistry,Departments at LTH,Faculty of Engineering, LTH(Swepub:lu)ok2-uni (author)
  • Groffen, JohnChildren's Hospital Los Angeles (author)
  • Grice, I. DarrenGriffith University (author)
  • Heisterkamp, NoraChildren's Hospital Los Angeles (author)
  • Blanchard, HelenGriffith University (author)
  • Griffith UniversityChildren's Hospital Los Angeles (creator_code:org_t)

Related titles

  • In:Journal of Medicinal Chemistry: American Chemical Society (ACS)65:8, s. 5975-59890022-26231520-4804

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view